NASDAQ:CAPR Capricor Therapeutics (CAPR) Stock Price, News & Analysis $17.63 -1.29 (-6.82%) (As of 11:30 AM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Capricor Therapeutics Stock (NASDAQ:CAPR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Capricor Therapeutics alerts:Sign Up Key Stats Today's Range$17.02▼$19.8350-Day Range$4.18▼$21.9952-Week Range$2.90▼$23.40Volume1.41 million shsAverage Volume1.15 million shsMarket Capitalization$801.64 millionP/E RatioN/ADividend YieldN/APrice Target$34.50Consensus RatingBuy Company OverviewCapricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Read More… Tesla Execs are Freaking Out (Ad)It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.Click here to get the details. Capricor Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks77th Percentile Overall ScoreCAPR MarketRank™: Capricor Therapeutics scored higher than 77% of companies evaluated by MarketBeat, and ranked 266th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingCapricor Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCapricor Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Capricor Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Capricor Therapeutics are expected to grow in the coming year, from ($1.22) to ($0.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Capricor Therapeutics is -16.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Capricor Therapeutics is -16.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCapricor Therapeutics has a P/B Ratio of 11.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted11.61% of the outstanding shares of Capricor Therapeutics have been sold short.Short Interest Ratio / Days to CoverCapricor Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Capricor Therapeutics has recently decreased by 14.56%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCapricor Therapeutics does not currently pay a dividend.Dividend GrowthCapricor Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted11.61% of the outstanding shares of Capricor Therapeutics have been sold short.Short Interest Ratio / Days to CoverCapricor Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Capricor Therapeutics has recently decreased by 14.56%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.46 News SentimentCapricor Therapeutics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 22 news articles for Capricor Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 9 people have searched for CAPR on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Capricor Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $14,999,998.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders12.00% of the stock of Capricor Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 21.68% of the stock of Capricor Therapeutics is held by institutions.Read more about Capricor Therapeutics' insider trading history. Receive CAPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CAPR Stock News HeadlinesCapricor Therapeutics granted ODD, ATMP status for deramiocel by EMANovember 20 at 7:51 PM | markets.businessinsider.comCapricor wins key EU designations for the lead assetNovember 20 at 2:50 PM | msn.comBreaking News: Tesla headed to $500…That headline hit late last night…and the rally has begun Which is why we want to urge you to go ahead and download Lance’s e-Book now outlining his bullish case for Tesla. November 21, 2024 | WealthPress (Ad)Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines AgencyNovember 20 at 9:47 AM | markets.businessinsider.comWhat is HC Wainwright's Forecast for CAPR FY2024 Earnings?November 20 at 2:25 AM | americanbankingnews.comJones Trading Initiates Coverage of Capricor Therapeutics (CAPR) with Buy RecommendationNovember 18 at 7:05 PM | msn.comCapricor Therapeutics initiated with a Buy at JonesResearchNovember 18 at 7:05 PM | markets.businessinsider.comStrong Buy Rating for Capricor Therapeutics Driven by Deramiocel’s Promising Potential in DMD Treatment and Strategic PartnershipsNovember 18 at 7:05 PM | markets.businessinsider.comSee More Headlines CAPR Stock Analysis - Frequently Asked Questions How have CAPR shares performed this year? Capricor Therapeutics' stock was trading at $4.89 at the beginning of 2024. Since then, CAPR stock has increased by 256.4% and is now trading at $17.43. View the best growth stocks for 2024 here. How were Capricor Therapeutics' earnings last quarter? Capricor Therapeutics Inc (NASDAQ:CAPR) posted its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.05. Capricor Therapeutics had a negative net margin of 146.86% and a negative trailing twelve-month return on equity of 112.95%. Who are Capricor Therapeutics' major shareholders? Top institutional investors of Capricor Therapeutics include Geode Capital Management LLC (1.41%), State Street Corp (1.13%), Ikarian Capital LLC and Point72 Asset Management L.P. (0.55%). Insiders that own company stock include Shinyaku Co Ltd Nippon, David B Musket, Paul Gisbert Auwaerter and Xavier Avat. View institutional ownership trends. How do I buy shares of Capricor Therapeutics? Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Capricor Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Capricor Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Moderna (MRNA), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings11/08/2021Today11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CAPR CUSIPN/A CIK1133869 Webwww.capricor.com Phone310-358-3200Fax415-875-7075EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$34.50 High Stock Price Target$77.00 Low Stock Price Target$15.00 Potential Upside/Downside+86.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,290,000.00 Net Margins-146.86% Pretax Margin-146.86% Return on Equity-112.95% Return on Assets-57.00% Debt Debt-to-Equity RatioN/A Current Ratio4.19 Quick Ratio4.19 Sales & Book Value Annual Sales$25.18 million Price / Sales33.50 Cash FlowN/A Price / Cash FlowN/A Book Value$1.50 per share Price / Book12.37Miscellaneous Outstanding Shares45,470,000Free Float40,014,000Market Cap$843.47 million OptionableOptionable Beta4.00 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:CAPR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.